01—Abstract
Summary
Summary of the 10-K filed February 4, 2021. Cited figures are marked; the original filing is the authoritative source.
In 2020, 3M Company (MMM) demonstrated resilience, navigating the COVID-19 pandemic with a slight increase in net sales by 0.1% to $32.184 billiona, while net income attributable to 3M increased by 18.4% to $5.384 billion, or $9.25 per diluted share.
The company saw strong demand in personal safety products, including respirators, which significantly benefited sales amidst the pandemic. Despite these positive results, several segments experienced declines due to market weakness exacerbated by COVID-19, notably in oral care, advanced materials, and automotive/aerospace. The company continued to manage its portfolio, including the divestiture of its drug delivery business.
Management focused on cost control and operational efficiencies, leading to an improvement in operating income margins. Key risks highlighted include ongoing legal and regulatory proceedings, particularly related to PFAS (per- and polyfluoroalkyl substances), and global economic uncertainties. 3M also maintained a strong liquidity position and continued its commitment to returning capital to shareholders through dividends.
02—Key points
Key Highlights
- Total net sales increased slightly by 0.1% to $32.184 billion in 2020.
- Net income attributable to 3M increased by 18.4% to $5.384 billion, or $9.25 per diluted share.
- Strong growth in the Personal Safety division, driven by demand for respirators due to COVID-19, partially offset weakness in other segments.
- Significant declines were noted in Oral Care (-19%), Advanced Materials (-17%), and Automotive & Aerospace (-16%) due to market softness, partly attributed to COVID-19.
- Operating income margins improved by 3.1 percentage points, reflecting cost-saving measures and improved operational performance.
- The company generated $8.1 billion in operating cash flow and $6.6 billion in free cash flow.
- 3M announced its intention to resume share repurchases in 2021 and increased its quarterly dividend by 1%.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, 3M Co kept $0.17.
- Revenue$32.18B100.0%
- Cost of revenue−$16.61B51.6%
- Gross profit$15.58B48.4%
- Operating costs−$8.42B26.2%
- Operating income$7.16B22.3%
- Interest, other & tax−$1.71B5.3%
- Net income$5.45B16.9%
Where FY2020 revenue went
$32.18B- Cost of revenue: $16.61B, 52% of revenue
- SG&A: $6.93B, 22% of revenue
- Net income: $5.45B, 17% of revenue
- R&D: $1.10B, 3.4% of revenue
- Other operating costs: $389.0M, 1.2% of revenue
- Interest, other & tax: $1.71B, 5.3% of revenue
Kept 17% as net incomeOther operating costs $389.0M · 1.2%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 4, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $32.18B$32.14B | +0.1% |
| Cost of Revenue | $16.61B$17.14B | −3.1% |
| Gross Profit | $15.58B$15.00B | +3.9% |
| R&D Expenses | $1.10B$1.25B | −12.2% |
| SG&A Expenses | $6.93B$7.03B | −1.4% |
| Operating Expenses | $25.02B$25.96B | −3.6% |
| Operating Income | $7.16B$6.17B | +16.0% |
| Interest Expense | $529.00M$448.00M | +18.1% |
| Net Income | $5.45B$4.52B | +20.6% |
| EPS (Basic) | $9.43$7.83 | +20.4% |
| EPS (Diluted) | $9.36$7.72 | +21.2% |
| Shares Outstanding (Basic) | 577.60M577.00M | +0.1% |
| Shares Outstanding (Diluted) | 582.20M585.10M | −0.5% |
05—Questions
Frequently Asked Questions
How did COVID-19 impact 3M's performance in 2020?
COVID-19 had a mixed impact. It significantly boosted demand for personal safety products, especially respirators, driving strong sales in that segment. However, it also led to weakness in several other end markets, such as automotive, aerospace, and consumer-related businesses, resulting in sales declines in those areas. The company implemented various measures to protect employees and maintain business continuity.
What are the major litigation or legal risks facing 3M?
3M faces significant litigation and regulatory risks primarily related to PFAS (per- and polyfluoroalkyl substances) and respirator mask/asbestos claims. The company has recorded substantial charges and continues to navigate ongoing legal proceedings, regulatory inquiries, and potential liabilities associated with these issues. These matters could materially affect financial results.
What is 3M's approach to capital allocation and shareholder returns?
3M's capital allocation priorities include investing in organic growth (R&D, CapEx), pursuing complementary acquisitions, and returning capital to shareholders through dividends and share repurchases. The company suspended share repurchases temporarily in early 2020 due to COVID-19 uncertainty but plans to resume them in 2021 and continued its trend of increasing dividends, marking its 63rd consecutive annual increase.
06—Continue